Navigation Links
Genentech/Roche's Lucentis and Eli Lilly's Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
Date:9/24/2007

Longer Term Growth of Diabetic Neuropathy Market Will Be Driven by Launches of Disease-Modifying Therapies, According to a New Report from Decision

Resources

WALTHAM, Mass., Sept. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that by 2016 Genentech/Roche's Lucentis and Eli Lilly's ruboxistaurin will drive the markets for the treatment of diabetic retinopathy and diabetic nephropathy.

The new Pharmacor report entitled Diabetic Complications: Retinopathy, Neuropathy, and Nephropathy finds that, over the next decade, treatment of diabetic complications will expand considerably beyond tight control of blood pressure and glucose levels. Lucentis and ruboxistaurin will come the closest to achieving blockbuster status as treatments for diabetic complications in the world's major pharmaceutical markets -- the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Additionally, although promising drug classes with potential disease-modifying activity that include PKC inhibitors and aldose reductase inhibitors have suffered a decade of setbacks and disappointing efficacy data, the report finds that longer-term market growth will be driven by several of these novel therapies.

Therapies for the painful symptoms of diabetic neuropathy will continue to dominate sales, and few patients suffering non-painful diabetic neuropathy will receive treatment until the launches of disease-modifying therapies near the midpoint of the 2006-2016 forecast period.

"The diabetic neuropathy market will experience growth during the second half of our study period because of increasing use of Pfizer's antiepileptic drug, Lyrica, and Eli Lilly's antidepressant Cymbalta, which are both approved specifically for the treatment of diabetic neuropathic pain," said Donny Wong, Ph.D., analyst at Decision Resources. "Longer term
'/>"/>

SOURCE Decision Resources
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. FDA Approval For Lucentis
2. Ruboxistaurin (RBX) may prevent vision loss in diabetic patients
3. Ruboxistaurin As A Novel Treatment For Diabetic Nephropathy
4. Sleepy drivers increase road death toll
5. Traffic Violations Result in Safer Drivers
6. Dyslexia may slow a drivers reaction time as much as moderate drinking!!
7. Study suggests symptom driven therapy for adults with asthma
8. Peppermint or cinnamon smell can make drivers more alert
9. Mechanical forces drive early heart development
10. Measles Vaccination Drive Intensified In Quake-Hit Pakistan
11. More Funds Are Required For Immunisation Drive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... jacket is a hip- or waist-length garment for the ... in the front or slightly on the side. A ... a coat, which is outerwear. Some jackets are fashionable, ... well-known clothing manufacturer and retailer, has delightedly released its ... are offered at extremely low prices? , The ...
(Date:9/18/2014)... Older people become more physically vulnerable during bereavement, new ... hormones during bereavement changes with age, British researchers say. ... more likely to have weakened immune systems and develop ... and months after loss, we can suffer from reduced ... white blood cell and as such are essential at ...
(Date:9/18/2014)... Limited spots remain at Becker's Healthcare's upcoming ... are still available for Becker's ASC 21st Annual Meeting ... 23-25, 2014 at the Swissotel Chicago. , Only 10 ... Strategy Roundtable on November 4, 2014 at the Ritz ... Hospital Review Chief Executive Officer Strategy Roundtable on November ...
(Date:9/18/2014)... Angeles, CA (PRWEB) September 18, 2014 ... manufacture and refine carbon dioxide, selling it to downstream ... largest markets for carbon dioxide are food and beverage ... products, such as fruits, vegetables or pizzas. The gas ... Beverage manufacturers use the compound to carbonate soft drinks, ...
(Date:9/18/2014)... HealthDay Reporter , THURSDAY, Sept. 18, 2014 (HealthDay ... can quickly alter the way brain cells communicate with one ... Sept. 18 in Current Biology , are a step ... Experts said the hope is to eventually be able to ... a drug -- and which people would fare better with ...
Breaking Medicine News(10 mins):Health News:Cool Jackets Are For Sale At Fecbek.com 2Health News:Grief Can Weigh on Immune System in Older Folks, Study Says 2Health News:Limited Spots Remain at Becker's Upcoming ASC and Hospital Conferences 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Carbon Dioxide Production in the US Industry Market Research Report Now Available from IBISWorld 3Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 2Health News:One Dose of Antidepressant Changes Brain Connections, Study Says 3
... States Senate Committee on Small Business and Entrepreneurship ... J. Snowe, R-Maine, today convened a roundtable to ... small businesses. Participants at the roundtable, entitled "Healthcare ... of Small Businesses," included U.S. Sen. Ron Wyden, ...
... -- Skyrocketing prescription drug prices are stinging Illinoisans over the ... the basics, like food and utilities, in order to afford needed ... drugs see record price increases, the majority of the state,s 50 ... medications in the coming year. , , "No ...
... "Keratosis Pilaris," "Keratosis Pilaris." Hmm, sounds weird, doesn,t it? ... to the American Academy of Dermatology nags 40 percent of ... family of moisturizers is launching www.littleredbumps.com , ... associated with Keratosis Pilaris also known as KP. , ...
... OAKLAND, Calif., July 9 Members of SEIU UHW ... outside the Oakland Federal Building, 1301 Clay Street, to release newly ... former top union officials were advised by their attorney that some ... and then followed their lawyer,s advice on how to cover them ...
... can cause menstrual woes, infertility, researchers note , THURSDAY, ... bring some relief to the one in 10 women ... disease called polycystic ovarian syndrome (PCOS). , ... hormones -- including testosterone -- and often develop ovarian ...
... chest pain patients in the emergency department, instead of the ... length of stay and hospital charges, according to a study ... WA. The SOC workup, which is timely and expensive, consists ... stress testing. , , Fifty patients were included in ...
Cached Medicine News:Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 2Health News:Landrieu, Snowe Convene Roundtable on Healthcare for Small Businesses 3Health News:High Rx Costs Hammering Illinois' 50+ Population 2Health News:Video: What Are Those Little Red Bumps? 2Health News:Video: What Are Those Little Red Bumps? 3Health News:Newly Obtained Information Shows That Ousted Union Leaders Plotted and Covered Up Wrongdoing 2Health News:Acupuncture, Exercise May Ease Polycystic Ovarian Syndrome 2
(Date:9/18/2014)... Sept. 18, 2014  Aratana Therapeutics, Inc. (NASDAQ: ... focused on licensing, developing and commercializing innovative biopharmaceutical ... exercise of the underwriters, option to purchase 675,000 ... the company,s previously announced public offering of 4,500,000 ... are being offered by Aratana Therapeutics.  With the ...
(Date:9/18/2014)... , Sept. 18, 2014 Research and ... Market Monitor : Global Chiral Separation Columns Market" ... chromatography is a technique involving two enantiomers of the ... consisting of a single enantiomer, thus possessing different elution ... such as cellulose. The chiral separation chromatography ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources ... the United States , 54 ... GlaxoSmithKline,s BRAF inhibitor Tafinlar for BRAF -mutation-positive ... who have prescribed GlaxoSmithKline,s MEK inhibitor Mekinist. Among ... percentage (42 percent and 43 percent, respectively) expects ...
Breaking Medicine Technology:Aratana Therapeutics, Inc. Announces Full Exercise of Underwriters' Option to Purchase Additional Shares 2Micro Market Monitor: Global Chiral Separation Columns Market 2At One Year Post-Launch, Approximately One Half of Surveyed U.S. Medical Oncologists Have Prescribed Single-Agent Tafinlar and Mekinist to Their Malignant Melanoma Patients 2
... The award recognizes outstanding journalism demonstrating the ... discoveries and scientific,breakthroughs., WASHINGTON, June 19 ... announces the winners of the 7th Annual,Michael ... in honor of FBR,s,Chairman and 2008 Congressional ...
... Kendle (Nasdaq: KNDL ), a,leading global full-service ... its experts will present at the upcoming Drug,Information ... scheduled,for June 22-26, 2008, at the Boston Convention ... speak on key topics in the clinical,development industry, ...
Cached Medicine Technology:The Foundation for Biomedical Research Announces Winners of the 7th Annual Michael E. DeBakey Journalism Awards 2Kendle Experts to Present at the Drug Information Association 44th Annual Meeting 2Kendle Experts to Present at the Drug Information Association 44th Annual Meeting 3
... Pipetman Ultra is a fully adjustable, air-displacement ... It is the latest member of the ... characteristics: robustness, accuracy, and precision. We also ... feedback from our customers. Eight models cover ...
... cover the range from 2ul to 5000ul. ... lock design prevents inadvertent volume change. Novel ... Whole pipette is autoclavable at 121C(250F). To ... Suitable for one-handed operation. Auto or ...
... offers improved ergonomics for today's exacting ... grippy finger rest and the large ... efficiency. Finnpipette Digitals also feature soft-touch ... (pat. pend.) and super blow-out for ...
... In the specialty areas ... or intensive care work, it ... in your practice. Alokas motorized ... Doppler and Tissue Harmonic Echo ...
Medicine Products: